e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Interstitial lung diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification?
Vanessa Maria Ferreira dos Santos (Ovar, Portugal), Vanessa Santos, Eva Padrão, Inês Neves, Natália Melo, Patrícia Mota, Rui Cunha, José Pereira, António Morais
Source:
International Congress 2015 – Interstitial lung diseases II
Session:
Interstitial lung diseases II
Session type:
Thematic Poster Session
Number:
3844
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vanessa Maria Ferreira dos Santos (Ovar, Portugal), Vanessa Santos, Eva Padrão, Inês Neves, Natália Melo, Patrícia Mota, Rui Cunha, José Pereira, António Morais. Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification?. Eur Respir J 2015; 46: Suppl. 59, 3844
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Mortality and survival predictor in chronic hypersensitivity pneumonitis
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Familial pulmonary fibrosis: Clinical-functional and radiological features
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Emphysematous changes in chronic hypersensitivity pneumonitis: A retrospective analysis of 12 patients
Source: International Congress 2016 – Orphan diseases II
Year: 2016
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Chronic interstitial lung disease in children: diagnosis and treatment
Source: International Congress 2016 – PG6 Lung fibrosis and sarcoidosis
Year: 2016
A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Primary pulmonary interstitial glycogenosis. Long term outcome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Aetiological panorama in the diagnosis of interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014
Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014
Interstitial lung disease caused by designer drugs
Source: International Congress 2015 – A morphological view of chest pathology
Year: 2015
Usual interstitial pneumonia preceding rheumatoid arthritis: Clinical, imaging, and histopathologic features
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Can current guidelines improve the diagnosis of a usual interstitial pneumonia among general radiologists?
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept